Are the indications for postoperative radiotherapy in the NCCN guidelines for patients with gastric adenocarcinoma too broad? A study based on the SEER database

Ze-Ning Huang1,2,3,4, Qi-Yue Chen1,2,3,4, Chao-Hui Zheng1,2,3,4, Ping Li1,2,3,4, Jian-Wei Xie1,2,3,4, Jia-Bin Wang1,2,3,4, Jian-Xian Lin1,2,3,4, Jun Lu1,2,3,4, Long-Long Cao1,2,3,4, Mi Lin1,2,3,4, Ru-Hong Tu1,2,3,4, Ju-Li Lin1,2,3,4, Hua-long Zheng1,2,3,4 and Chang-Ming Huang1,2,3,4*

Abstract

Background: The types of patients with gastric adenocarcinoma (GA) for whom postoperative radiotherapy can improve the disease-specific survival rate (DSS) remain controversial. This study aims to explore the ideal indications.

Methods: Patients in the Surveillance, Epidemiology, and End Results (SEER) database with T3–4Nx or TxN+ GA from January 1988 to December 2012 were included and divided into a postoperative chemoradiotherapy group (Group R) and a postoperative chemotherapy group (Group C). We established a nomogram to predict DSS and then divided entire patient cohort into low-risk and high-risk groups based on the DSS predicted by the nomogram.

Results: The Cox multiple regression analysis demonstrated that various risk factors affected DSS for Group R. Based on these risk factors, a nomogram for predicting DSS was established. The decision curve indicated that the best clinical effect could be obtained when the threshold probability was 0–58%. The patients were then divided into low-risk (< 69 points) and high-risk (≥ 69 points) groups according to the five-year DSS predicted. DSS was significantly better for Group R than for Group C for high-risk patients (P < 0.001) but was similar for low-risk patients (P = 0.732).

Conclusion: At present, the National Comprehensive Cancer Network (NCCN) guidelines may include an overly broad range of indications for postoperative radiotherapy for patients with GA. For intestinal GA patients with a postoperative pathologic stage of T1 N1 who are younger than 65 years, have had more than 15 lymph nodes dissected, and have received postoperative chemotherapy, postoperative radiotherapy should not be recommended.

Keywords: Postoperative radiotherapy, Indication, NCCN guidelines, Disease-specific survival rate, Nomogram, Decision curve

* Correspondence: hcmlr2002@163.com
1Department of Gastric Surgery, Fujian Medical University Union Hospital, No.29 Xinquan Road, Fuzhou 350001, Fujian Province, China
2Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Although the morbidity of gastric adenocarcinoma (GA) has declined in recent years, this disease remains the fourth most fatal malignancy in the world [1, 2]. At present, surgery is the only reliable cure for GA [3–5]. Regional recurrence and distant metastasis are the main causes of reduced survival among patients with GA [6, 7]. However, postoperative adjuvant chemoradiotherapy can reduce the risks of regional recurrence and distant metastasis [8–12]. Therefore, the rational use of postoperative chemoradiotherapy can improve patient prognoses. The effects of postoperative adjuvant chemotherapy have been widely recognized. In contrast, although the NCCN guidelines for GA that exhibits mitosis [13] clearly suggest that a postoperative pathological stage of T3–4Nx or TxN+ indicates the feasibility of adjuvant chemoradiotherapy after surgery, which means that postoperative radiotherapy is based on postoperative chemotherapy, a portion of patients who undergo radiotherapy experience severe postoperative complications [14–16], and the curative effects of radiotherapy are influenced by various pathological factors. As a result, the indications for postoperative radiotherapy remain controversial [17]. Thus, the purpose of this study was to use the Surveillance, Epidemiology, and End Results (SEER) database to explore risk factors for prognosis for patients who undergo postoperative radiotherapy; perform stratified analyses of the effects of radiotherapy on postoperative disease-specific survival rate (DSS) for patients with GA; construct a nomogram to filter out patients who are unsuitable for postoperative radiotherapy; and provide a reference for the reasonable implementation of postoperative radiotherapy.

Methods
Study population and evaluation parameters
Between January 1988 and December 2012, data were collected from patients with GA of pathological stage T3–4Nx or TxN+ from the SEER database (registration number: 14088-Nov2015). For all cases, tumor stages were reevaluated using the 7th American Joint Committee on Cancer (AJCC) TNM staging system (October 2016) [18].

The inclusion criteria were (1) GA had been confirmed via biopsy; (2) the primary site was limited to the stomach; (3) the patient had undergone gastrectomy; (4) the patient had received postoperative chemoradiotherapy or postoperative chemotherapy; and (5) the pathological stage was T3–4Nx or TxN+. The exclusion criteria were (1) the patient had received preoperative radiotherapy, intraoperative radiotherapy, or radiotherapy and surgery in an uncertain sequence; (2) there was incomplete basic information (including race, gender, and age, among other characteristics) for the patient; (3) distant metastasis had occurred; (4) the pathologic diagnosis was incomplete, and tumor stage could not be accurately assessed; and (5) survival information was unclear. Ultimately, 12,329 cases were included; patients were divided into a postoperative chemoradiotherapy group (Group R, n = 7424) and a postoperative chemotherapy group (Group C, n = 4905).

Sociodemographic and clinicopathological data were routinely collected. Race was divided into three groups: white, black and other (which included American Indian, Alaskan Native, Asian, and Pacific Islander). Age was divided into two groups (≤ 65 years and > 65 years) in accordance with international standard survival classification categories for age [14]. Using the X-tile program, optimal thresholds for tumor size (based on the longest diameter) were applied to classify the patients into the following groups: < 55 mm, ≥ 55 mm, linitis plastica, and size could not be assessed. Tumor sites were divided into the following four subsite categories: middle and distal third (C16.2, C16.3, and C16.4); proximal third (C16.0 and C16.1); stomach, NOS (C16.5, C16.6, and C16.9); and overlapping (C16.8). The tumors were pathologically categorized as low grade (well and moderately differentiated), high grade (poorly differentiated and undifferentiated) and Gx grade (grade could not be evaluated). With respect to histological type, tumors were categorized as intestinal (8144/3) and other. Variables in the SEER database that have not been mentioned above, such as complications, postoperative complications and incision, were not included in the study. Disease-specific survival time was calculated from the date of surgery until the time of death due to GA or another cause (such as pneumonia or coronary heart disease), and cases for which a follow-up termination event had not yet occurred were excluded from consideration.

Statistical analysis
Measurement data were examined using chi-square tests or Fisher’s exact test, and enumeration data were analyzed using t-tests or the Mann-Whitney U test. Survival curves were created using the Kaplan-Meier method, and log-rank tests were used to assess between-group differences. The independent risk factors that affected DSS for patients who received radiation were identified using a Cox regression model. A nomogram for predicting DSS was established, and the accuracy of this nomogram was quantified using Harrell’s concordance index (C-index). Internal validation involved the adoption of the calibration curve and 1000 repeats. A plot was produced in which the real line represents actual values and the dotted line represents predicted values. Recursive partitioning was used to choose the most appropriate cutoff point dividing the nomogram to predict 5-year DSS. The analysis process is as follows. The total score of the whole patient cohort is divided into < A, ≥ A, two parts, and gradually under different cutoff points (A) to compare the two parts of the patient’s DSS, until the
cut-off point that results in the most significant difference between the two parts is identified [19, 20]. In this study, when A = 69, patients with a score < 69 and > 69 showed the most significant difference in DSS (p < 0.001). The decision curve verified the application of the nomogram; the Y-axis in the figure represents the benefit of postoperative radiotherapy, the X-axis represents the threshold probability, the horizontal full lines represent the benefit of all the patients that did not receive postoperative radiotherapy, the oblique full line represents the benefit according to the nomogram scores to decide whether a patient should accept postoperative radiotherapy. The threshold for statistical significance was set at P < 0.05. Statistical analyses were performed using SPSS® for Windows® version 19.0 (IBM, Armonk, New York, USA), X-tile and R version 3.2.3 (http://www.r-project.org).

**Results**

**Between-group comparisons of overall patient characteristics**

Table 1 presents comparisons of general clinical data for the patients in Group R and Group C. There were significant differences between the two groups of patients with respect to gender, race, age, tumor infiltration depth, lymph node metastasis, lymph node number, whether more than 15 lymph nodes were dissected, tumor size, and tumor differentiation grade (P < 0.05 for all comparisons). The two groups did not significantly differ with respect to histological type (P > 0.05).

**The nomogram for DSS in group R**

Additional file 1 Table S1 shows results from univariate and multivariate Cox regressions, which were used to predict DSS for Group R. After stepwise backward variable selection, only age, tumor infiltration depth, lymph node metastasis, whether more than 15 lymph nodes were dissected, and histological type (P < 0.05) remained in the final model. The final model served as the basis for a multivariate nomogram (Fig. 1). Nomogram predictions are shown for the 3-year and 5-year time points (C-index = 0.704). Additional file 1 Table S2 shows the cut-off point for risk factors affecting disease-free survival (DSS), and the sum of each factor’s point value is the total score for each patient. The calibration curve (Additional file 2: Figure S1) suggested that the predicted values were consistent with the actual values.

**Stratification of the patients in the two groups by nomogram score**

In this study, recursive partitioning analysis indicated that the optimal cut-off point for nomogram-predicted 5-year DSS was 69. All of the patients were divided into two groups using this cut-off point, with patients with < 69 and ≥ 69 points categorized as low- and high-risk patients, respectively. Then, the T3–4 Nx and T4N+ patients were combined with those meeting the inclusion criteria, and the flow chart of high-risk patients and low-risk patients is shown in Fig. 2.

**Comparisons of DSSs for the two groups for patients with different risk levels**

Additional file 3 Figure S2 presents a comparison of DSSs for the two groups. DSS was significantly better for Group R than for Group C (log-rank < 0.001). Further stratification analysis revealed that DSS was significantly better for Group R than for Group C for high-risk patients (log-rank < 0.001; Fig. 3) but that the DSSs for the two groups did not significantly differ for low-risk patients (log-rank = 0.732; Fig. 4).

**The decision curve**

A decision curve was established based on the nomogram (Fig. 5). The results showed that when the threshold probability is 0–58%, the benefit of the oblique line (whether to administer radiotherapy in the population according to the nomogram score) is greater than that of the horizontal full line (no radiotherapy for the patients) and the oblique full line (provide radiotherapy for the entire population); in other words, the maximum benefit for the patients can be obtained, which means that in cases involving a tumor of pathological stage T3–4Nx or T4N+, postoperative radiation should be administered to patients with scores > 69 points. Compared to strategies in which all patients or no patients receive postoperative radiotherapy, this approach will maximize the curative effects of radiotherapy.

**Discussion**

In recent years, the clinical efficacy of postoperative chemoradiotherapy involving postoperative radiotherapy after postoperative chemotherapy has been confirmed for certain gastric cancer patients in randomized controlled trials [14, 21, 22]. However, although indications for postoperative adjuvant chemotherapy have been widely recognized, indications for postoperative adjuvant radiation therapy remain unclear. It is generally believed that the latter indications are influenced not only by TNM stage but also by factors such as the number of lymph nodes dissected and pathological classification [23]. The current NCCN guidelines suggest that gastric cancer patients with pathological staging of T3–4 Nx or T4N+ should accept postoperative radiotherapy; these guidelines use TNM stage as the sole determinant of whether postoperative radiotherapy should be performed and thus cannot be applied in clinical contexts. In the present

Huang et al. BMC Cancer (2018) 18:1064
**Table 1** Demographic and Clinicopathologic Variables of the Development and Validation Cohorts

| Variable                        | Chemoradiotherapy Cohort\(n = 7424\) | Chemotherapy Cohort\(n = 4905\) | \(\chi^2\)test | P     |
|---------------------------------|--------------------------------------|---------------------------------|----------------|-------|
| **No. of Patients**              |                                      |                                 |                |       |
| **Sex**                         |                                      |                                 |                |       |
| Female                          | 2705                                 | 1805                            |                | .000  |
| Male                            | 4719                                 | 3100                            |                |       |
| **Race**                        |                                      |                                 |                | .000  |
| Black                           | 1033                                 | 606                             |                | 12.4  |
| Other (American Indian/AK Native, Asian/Pacific Islander) | 1628 | 1007 | 20.5 |
| White                           | 4763                                 | 3292                            |                | 67.1  |
| **Age y**                       |                                      |                                 |                | .000  |
| \(\leq 65\)                    | 4314                                 | 2656                            |                | 54.1  |
| > 65                            | 3110                                 | 2249                            |                | 35.9  |
| **Depth of invasion**           |                                      |                                 |                | .000  |
| Mucosa/Submucosa                | 448                                  | 273                             |                | 5.6   |
| Proper muscle                   | 622                                  | 321                             |                | 6.5   |
| Subserosa                       | 2877                                 | 1858                            |                | 37.9  |
| Serosa                          | 2700                                 | 1692                            |                | 34.5  |
| Adjacent organ invasion         | 777                                  | 761                             |                | 15.5  |
| **Metastatic LNs, No.**         |                                      |                                 |                | .000  |
| 0                               | 1033                                 | 866                             |                | 17.7  |
| 1–2                             | 1883                                 | 1260                            |                | 25.7  |
| 3–6                             | 2047                                 | 1186                            |                | 24.2  |
| 7–15                            | 1855                                 | 1096                            |                | 22.3  |
| >15                             | 606                                  | 497                             |                | 10.1  |
| **LNs dissection, No.**         |                                      |                                 |                | .000  |
| \(>15\)                        | 3474                                 | 2567                            |                | 47.7  |
| \(\leq 15\)                    | 3950                                 | 2338                            |                | 52.3  |
| **Size mm**                     |                                      |                                 |                | .000  |
| \(<55\)                        | 3670                                 | 2193                            |                | 44.7  |
| \(\geq 55\)                    | 3144                                 | 2038                            |                | 41.5  |
| **Size of tumor cannot be assessed** | 610 | 674 | 13.7 |
| **Primary Site**                |                                      |                                 |                | .000  |
| Proximal third                  | 1590                                 | 1135                            |                | 23.1  |
| Mid                             | 2256                                 | 1372                            |                | 28.0  |
| Distal third                    | 2335                                 | 1429                            |                | 29.1  |
| Stomach, NOS                    | 574                                  | 436                             |                | 8.9   |
| Overlapping lesion of stomach   | 669                                  | 533                             |                | 10.9  |
| **Grade**                       |                                      |                                 |                | .000  |
| Low                             | 5499                                 | 3632                            |                | 74.0  |
| High                            | 1672                                 | 1025                            |                | 20.9  |
| Gx                              | 253                                  | 248                             |                | 5.1   |
| **Histology adenocarcinoma**    |                                      |                                 |                | .751  |
| Other types                     | 6566                                 | 4348                            |                | 88.6  |
| Intestinal type                 | 858                                  | 557                             |                | 11.4  |
| **AJCC 7th staging**            |                                      |                                 |                | .000  |
study, the SEER database was used to investigate more accurate decision factors for postoperative radiotherapy and thereby determine stricter indications for this therapeutic modality. The results show that not all these patients require postoperative radiotherapy, and we suggest that high-risk patients should accept postoperative radiotherapy, whereas low-risk patients should not.

Defining risk factors that influence DSS is an approach for studying indications for postoperative radiotherapy. Thus, each of the indicators in this study was an independent risk factor for DSS according to Multiple Cox regression analysis. Prior studies have demonstrated that more advanced TN stage, larger tumor diameter and a tumor pathology classification of diffuse can increase the difficulty of R0 tumor resection and thereby affect

| Variable | Chemoradiotherapy Cohort (n = 7424) | Chemotherapy Cohort (n = 4905) |
|----------|-----------------------------------|-------------------------------|
|          | No. of Patients | %  | No. of Patients | %  | \( \chi^2 \) test | \( P \) |
| Ib       | 544         | 7.3 | 332         | 6.8 |                |      |
| IIa      | 673         | 9.1 | 559         | 11.4 |                |      |
| IIb      | 1308        | 26.7 | 785         | 16.0 |                |      |
| IIIa     | 2230        | 30.0 | 1358        | 27.7 |                |      |
| IIIb     | 1883        | 25.4 | 1208        | 24.6 |                |      |
| IIc      | 786         | 10.6 | 663         | 13.5 |                |      |

Follow-up, month
- Median: Chemoradiotherapy Cohort = 26, Chemotherapy Cohort = 18
- Range: Chemoradiotherapy Cohort = 0–318, Chemotherapy Cohort = 0–319

Abbreviations: LN, lymph node; No., number; NOS, not otherwise specified; AJCC, American Joint Committee on Cancer; Gx, grade could not be evaluated

Fig. 1 The nomogram for DSS in Group R (C-index = 0.704)
patients’ postoperative DSS [24, 25]. Having fewer than 15 lymph nodes dissected can increase the possibility of postoperative lymph node recurrence [26, 27], which also decreases DSS. The results of this study are similar to those of previous studies. Furthermore, we established a nomogram for predicting DSS for patients who underwent postoperative chemoradiotherapy; after grading the two groups of patients, a cut-off for nomogram-predicted 5-year DSS was determined via recursive partitioning analysis. Subsequently, we stratified our analyses of DSS for patients in the two groups based on this cut-off (69 points). The results showed that for all patients, DSS was significantly better for Group R than for Group C. However, among low-risk patients, DSS did not significantly differ for the two groups, indicating that postoperative radiation did not appear to influence DSS for low-risk patients. This result led us to question whether patients in the low-risk group should be required to undergo postoperative radiotherapy. Previously, basic studies have reported that GAs are not sensitive to radiation; normal gastric mucosa cells will already be injured by the time that cancer cells have been exposed to a lethal dose of radiation. Moreover, viscera adjacent to the stomach, such as the liver, pancreas, and other organs, are sensitive to radiation injury. Given the invasiveness of surgery, which causes decreases in patients’ physical strength, additional
radiation can often be difficult for patients to tolerate. Therefore, a significant number of patients experience serious complications after postoperative radiotherapy [13–15]. The results of the present study indicate that for low-risk patients, DSS did not improve after postoperative radiotherapy. Therefore, we believe that postoperative radiotherapy is not appropriate for low-risk patients.

This study further verified the value of applying nomograms via decision curves. A decision curve is used as a simple mathematical model in which the loss function [28] is employed to examine the effectiveness of a statistical model for inferring the outcome of an event; such curves have been widely utilized to evaluate the usefulness and benefit of forecasting models [29–32]. The results of this study showed that when the threshold probability is 0–58%, clinicians should make decisions regarding whether radiotherapy should be administered to patients for whom this treatment is suggested by NCCN guidelines. This approach can produce greater beneficial effects than having either all or none of these patients undergo radiotherapy. The threshold probability represents the clinician's degree of confidence in postoperative radiotherapy. We believe that if a patient is unable to tolerate complications associated with postoperative radiotherapy, the clinician's confidence in postoperative radiotherapy for patients with GA will be affected. Prior studies [13–15] have indicated that approximately 48–54% of patients with GA are unable to tolerate complications that arise after postoperative radiotherapy; therefore, we believe that clinicians should have approximately 50% confidence that postoperative radiation will benefit patients. This belief is consistent with the scope of application of the decision curve.

This study involved a large sample and long-term follow-up, and the obtained results were verified and validated. Nonetheless, there are a few limitations. First, a retrospective study may inevitably incorporate bias. Second, although SEER data from a single centralized repository offered the opportunity to examine a large sample, the SEER database is missing certain data regarding characteristics that affect outcomes, such as the positive margin rate and postoperative complications. Consequently, the results of this study may be insufficiently

**Fig. 4** Comparisons of DSSs for the two groups for low-risk patients (Log-rank < 0.001)

**Fig. 5** Decision curve based on the nomogram
accurate. Therefore, to confirm our findings, more rigorous results should be obtained from multi-center, prospective, large-sample clinical trials.

Conclusion
The nomogram established in this study can be effectively applied to clinical decision-making. Among patients for whom, T3—–4 Nx and TxN+ GA patients, NCCN guidelines would recommend postoperative radiotherapy, only the score of patient determined using the nomogram is > 69 should accept postoperative radiotherapy, but for the score < 69 points, postoperative radiotherapy should not be recommended, because there is no benefit for survival but serious complications.

Additional files

Additional file 1: Table S1. Univariate and Multivariate Cox Regression Model for Prediction of Disease-Specific Survival. Table S2. The point values for risk factors affecting disease-free survival. (DOCX 30 kb)
Additional file 2: Figure S1. Nomogram predicted probability of 5-year DSS (TIF 276 kb)
Additional file 3: Figure S2. Comparisons of DSSs for the two groups for all patients (Log-rank < 0.001). (TIF 35 kb)

Acknowledgements
The authors are thankful to Fujian Medical University Union Hospital for management of our gastric cancer patient database.

Funding
This study was funded by National Key Clinical Specialty Discipline Construction program of China (No. 201211649). Scientific and technological innovation joint capital projects of Fujian Province (2016Y9031).

Availability of data and materials
We declared that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality.

Authors’ contributions
ZNH, CQY, HCM conceived of the study, analyzed the data, and drafted the manuscript; CHZ, PL, JWX, BBMM, et al. Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus? [J]. Ann Surg Oncol. 2010;17(11):98–108.

7. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol. 2010;11(5):49–49.
8. Skoropad V, Bervod B. Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial[J]. Journal of surgical oncology. 2002;80(2):72–8. https://doi.org/10.1002/jso.10102.
9. Valentini V, Cellini F. Combined treatments in gastric cancer radiotherapy[J]. I supplementi di Tumori : official journal of Società italiana di cancerologia . [et al.], 2003;20(5):339–44.
10. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37.
11. Fiorica F, Carite F, Enea M, et al. The impact of radiotherapy on survival in respectable gastric carcinoma: a meta-analysis of literature data[J]. Cancer Treat Rev. 2007;33(8):729–40.
12. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction [J]. N Engl J Med. 2001;345(10):75–30.
13. Ajani JA, D’Amico TA, Alhanna K, et al. Gastric Cancer, version 3.2016. NCCN clinical practice guidelines in oncology[J]. Journal of the National Comprehensive Cancer Network . :JNCCN. 2016;14(10):1286–312.
14. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.
15. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.
16. Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with Capecitabine and cisplatin versus concurrent Chemoradiotherapy in gastric Cancer: final report of the adjuvant Chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6.
17. Goodman KA. Refining the role for adjuvant radiotherapy in gastric Cancer: risk stratification is key. J Clin Oncol. 2015 Oct 1;33(28):3082–4. https://doi.org/10.1200/JCO.2014.59.1941.
18. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.
19. Therneau TM, Atkinson EJ. An introduction to recursive partitioning using the RPART routine technical report 61. Rochester: Mayo Foundation; 1997.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
20. O’Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the international collaboration on oropharyngeal cancer network for staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17:440–51.

21. Fuchs CS, Tepper JE, Niedzwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol. 2011;29(15_suppl; abstr 4003):256s.

22. Zhu WG, Xia DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol. 2012;104(3):361–6.

23. Liang W, He J, Shen Y, et al. Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER database and a Chinese multi-institutional registry. J Clin Oncol. 2017 Apr 10;35(11):1162–70.

24. Hsu JT, Lin CJ, Sung CM, et al. Prognostic significance of the number of examined lymph nodes in node-negative GA. Eur J Surg Oncol. 2013;39:1287–93.

25. Shiraiishi N, Inomata M, Osawa N, et al. Early and late recurrence after gastrectomy for gastric carcinoma[J]. Cancer. 2000;89(2):255.

26. Lorenzon L, Mercantini P, Ferrè M, et al. Lymph-node ratio classification strongly correlates with cancer survivals of patients who underwent r0 resection for gastric cancer with more than 15 nodes harvested[J]. European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes. 2014;53(1–4):1–10. https://doi.org/10.1159/000360937.

27. Is retrieval of at least 15 lymph nodes sufficient recommendation in early gastric cancer?[J]. Annals of surgical treatment and research. 2014;87(4):180–4. https://doi.org/10.4174/astr.2014.87.4.180.

28. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565–74.

29. Fitzgerald M, Saville BR. Decision curve analysis[J]. JAMA. 2015;313(4):409–10. https://doi.org/10.1001/jama.2015.37.

30. Hernandez JM, Tsalatsanis A, Humphries LA, et al. Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis[J]. Annals of surgery. 2014;259(6):1208–14. https://doi.org/10.1097/SLA.0000000000000310.

31. Wynants L, Timmerman D, Verbakel J, et al. Clinical utility of risk models to refer patients with adnexal masses to specialized oncology care: multicenter external validation using decision curve analysis[J]. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017;23(2):468–74. https://doi.org/10.1158/1078-0432.CCR-16-0949.

32. Zastrow S, Brookman-May S, Cong TA, et al. Decision curve analysis and external validation of the postoperative Karakiewicz nomogram for renal cell carcinoma based on a large single-center study cohort[J]. World journal of urology. 2015;33(3):381–8. https://doi.org/10.1007/s00345-014-1321-6.